HSBC Holdings’s Citius Pharmaceuticals CTXR Stock Holding History

HSBC Holdings’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-612	Closed	-$9.2K	–	3014
2024 Q2	$9.2K	Hold	612	–	–	﹤0.01%	2897
2024 Q1	$13.7K	Buy	+612	New	+$11.2K	﹤0.01%	3010

Other funds holding CTXR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CCC

Chelsea Counsel Company Los Angeles, California $225M AUM 45.99% 1-Year Est. Return

HSBC Holdings's CTXR Position: Q3 2024 in Review

HSBC Holdings sold out of Citius Pharmaceuticals (CTXR) in Q3 2024, closing a stake of 612 shares — an estimated $9.2K sold.

HSBC Holdings first reported a position in CTXR in Q1 2024 and held it in 2 quarters. The position peaked at $13.7K in Q1 2024. 57 funds tracked by Wall St. Rank hold CTXR as of Q3 2024.

HSBC Holdings reported no remaining Citius Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
HSBC Holdings sold 612 Citius Pharmaceuticals shares in Q3 2024, an estimated $9.2K.
HSBC Holdings first reported a position in Citius Pharmaceuticals in Q1 2024 and held it in 2 quarters.
HSBC Holdings's Citius Pharmaceuticals position peaked at $13.7K in Q1 2024.
57 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2024.

Based on HSBC Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.